25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
The Minnesota Legislature recently passed, and Governor Walz signed, the Jobs and Economic Developme...
Read More >
In recent weeks, the National Labor Relations Board has issued several employer-friendly decisions, ...
Read More >
In recent years, North Carolina courts have become increasingly resistant to enforcing noncompetitio...
Read More >
On April 29, 2020, the Competition Bureau (Bureau) released a statement outlining its approach to an...
Read More >
Welcome to the 2019 Shearman & Sterling Antitrust Annual Report. Our seventh edition focuses on the...
Read More >
In June, Chandler, Arizona made headlines after partnering with Waymo to give city employees free tr...
Read More >